Clinical Trials - Surendar S. Purohit, M.D.

Research

Dr. Purohit is involved in multiple clinical trials that allow him to offer cutting-edge treatment to patients in a study atmosphere. Currently, Dr. Purohit is involved in multiple studies including those that target new treatments in diabetic retinopathy, macular degeneration, retinal vein occlusion and uveitis.

We are very honored to participate in these studies and are excited about the contribution they will make to future treatments in ophthalmology and patient care.

For a complete list of clinical trials in your area visit http://www.clinicaltrials.gov.

Sub-Investigator, 2007 – 2008
A Phase III, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion
Genentech, S. San Francisco, CA
Sub-Investigator, 2007 – 2008
A Phase III, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion
Genentech, S. San Francisco, CA
Sub-Investigator, 2007 – 2008
A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus
Genentech, S. San Francisco, CA
Sub-Investigator, 2007 – 2008
A 24-month Randomized, Double-Masked, Controlled MultiCenter Phase IIIB Study Assessing Safety and Efficacy of Verteporfin (Visudyne) Photodynamic Therapy Administered in Conjunction with Ranibizumab (Lucentis) Versus Ranibizumab (Lucentis) Monotherapy in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Novartis
Sub-Investigator, 2006 – 2008
A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals, New York, NY
Sub-Investigator, 2007 – 2008
A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals, New York, NY
Sub-Investigator, 2007 – 2008
A Phase I Open-Label, Dose Escalation Trial of REDD14NP Delivered by a Single Intravitreal Injection to Patients with Choroidal Neovascularization (CNV) Secondary to Exudative Age-Related Macular Degeneration (“Wet AMD”)
Principal Investigator
June 2011 – present
SAKURA 32-007
A phase 3, multinational, multicenter, randomized, double-masked, study assessing the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution for the treatment of non-infectious uveitis.
Sponsor: Santen, Inc
Sub Investigator
July 2011-present
VISTA VGFT-OD-1009
A double-masked, randomized, active-controlled, phase 3 study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with Diabetic Macular Edema
Sponsor: Regeneron
Sub Investigator
March 2011 – April 2013
SHORE FVF4967g A multicenter randomized study evaluation dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following retinal vein occlusion
Sponsor: Genetech
Principal Investigator
February 2012- present
iDEAL 2010-007-03- DME, Phase III study of the safety, tolerability., and bioactivity of repeated intravitreal injections of iC)-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in the treatment of diabetic macular edema.
Sponsor: Juvenile Diabetes Research Foundation International
Sub Investigator
April 2012 – present
VIBRANT, VGFTe-RVO-1027, a double-masked, randomized, active-controlled study of the efficacy, safety, and tolerability of intravitreal administration of VEGF Trap-eye (intravitreal Aflibercept injection [IAI]) in patients with macular edema secondary to Branch Retinal Vein Occlusion.
Sponsor: Regeneron
Sub Investigator
March 2913 – present
OSPREY, C-12-006 a prospective, randomized, double-masked, multi-center, two armed study comparing the efficacy and safety of ESBA 1008 versus Eylea ® in subjects with exudative age-related macular degeneration.
Sponsor: ALCON
Sub Investigator
March 2013 – present
XOMA, X052130/CL3-78989-005a study of safety and efficacy of Gevokizumab to treat active non-infectious uveitis.
Sponsor: Janix
Sub Investigator
January 2012 – present
Novartis CLFG316A 2203
A multi-center, randomized, sham control, proof of concept, study of patients with geographic atrophy associated with age-related macular degeneration, using Intravitreal LFG316 .
Sponsor: Novartis
Principal Investigator
August 2012 – present
L-Path LT 1009/iSONEP ™ (sonepcizumab) , a phase 2a, multicenter, masked, randomized, comparator-controlled study evaluation iSONEP ™ as either monotherapy or adjunctive therapy to Lucentis ® or Avastin® versus Lucentis ® or Avastin® alone for the treatment of subjects with choroidal neovascularization secondary to age-related macular degeneration.
Sponsor: L-Path, Inc.
Sub- Investigator
August 2013-present
AP-05-002 A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients with Diabetic Macular Edema
Sponsor: Ampio Pharmaceuticals, Inc.
Sub-Investigator
September-present
VGFTe-AMD-1124.02
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.
Sponsor: Regeneron Pharmaceuticals, Inc.
Sub Investigator
October-present
OPH1002 / PXL#212164
A phase 3 randomized, double-masked, control trial to establish the safety and efficacy of intravitreous administration of Fovista (anti PDGF-B pegylated aptamer) Administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
Sponsor:Opthotech